Close

Registration is free and only takes a moment. If you have already registered, please log in now.

Create Account
Forgot your password?
Log In
  • Links
  • Publisher Full Text
  • Authors
  • Kaji D
  • Miura Y
  • Takano T
  • MESH
  • Antineoplastic Agents
  • Female
  • Humans
  • Maintenance Chemotherapy
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms
  • Phthalazines
  • Piperazines

Unbound MEDLINE

Olaparib in platinum-sensitive ovarian cancer.

Links

  • Publisher Full Text

    • Authors

    Kaji D, Miura Y, Takano T

    Source

    The New England journal of medicine 367:2 2012 Jul 12 pg 179; author reply 179-80

    MeSH

    Antineoplastic Agents
    Female
    Humans
    Maintenance Chemotherapy
    Neoplasm Recurrence, Local
    Ovarian Neoplasms
    Phthalazines
    Piperazines

    Pub Type(s)

    Comment
    Letter

    Language

    eng

    PubMed ID

    22784123

    Related Citations

    • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
    • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
    • PARP inhibitors in cancer: moving beyond BRCA.
    • Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
    • Update on PARP1 inhibitors in ovarian cancer.
    • Concerns with "maintenance chemotherapy" for patients with recurrent platinum-sensitive ovarian cancer.
    • Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
    • Olaparib, PARP1 inhibitor in ovarian cancer.
    More
    unbound logo
    • Home »
    • Contact Us »
    • Help »
    • Privacy / Disclaimer »
    • Terms of Service »
    • Log In »
    • twitter
    • facebook
    © 2000–2013 Unbound Medicine, Inc. All rights reserved